Investigational drug · Phase 3
BMS-986278
Also called: Admilparant
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
19
Any phase or sponsor naming "BMS-986278"
First trial start
2023
Sep 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986278", any sponsor or status.
- Phase 115
Conditions studied
As listed on its trial records.
- Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986278" as an intervention, largest first.
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisPivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07441408 · 2,380 participants (planned) · Start Dec 16, 2026 · Primary completion Nov 22, 2029
Drug: BMS-986278 · For: Pulmonary Fibrosis
Sites: Birmingham, Alabama; Ocala, Florida; Philadelphia, Pennsylvania · 275 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06003426 · 1,255 participants · Start Sep 14, 2023 · Primary completion Oct 6, 2026
Drug: BMS-986278; BMS-986278 Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 390 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06025578 · 1,057 participants (planned) · Start Oct 25, 2023 · Primary completion Dec 27, 2027
Drug: BMS-986278; BMS-986278 Placebo · For: Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 459 sites in all
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04308681 · 403 participants · Start Jul 29, 2020 · Primary completion Aug 4, 2022
Drug: BMS-986278 · For: Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 119 sites in all
- A Study of Experimental Medication BMS-986278 Given to Healthy ParticipantsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03429933 · 112 participants · Start Feb 7, 2018 · Primary completion Mar 2, 2019
Drug: BMS-986278 · For: Healthy Participants
Sites: Groningen, Netherlands; London, United Kingdom
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06568458 · 71 participants · Start Sep 19, 2024 · Primary completion Feb 27, 2025
Drug: Nintedanib; BMS 986278 · For: Healthy Participants
Sites: Lenexa, Kansas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05684289 · 61 participants · Start Jan 3, 2023 · Primary completion May 2, 2023
Drug: BMS-986278; Sildenafil and 1 more · For: Healthy Participants
Sites: Cypress, California; Miami, Florida
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06715683 · 48 participants · Start Dec 12, 2024 · Primary completion Mar 16, 2025
Drug: BMS-986278 Batched method, Dose A; BMS-986278 Batched method, Dose B and 1 more · For: Healthy Volunteers
Sites: Anaheim, California
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05932303 · 47 participants · Start Jul 12, 2023 · Primary completion Oct 23, 2023
Drug: BMS-986278; Itraconazole and 2 more · For: Healthy Participants
Sites: Québec, Canada
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06746402 · 42 participants · Start Feb 10, 2025 · Primary completion Sep 11, 2025
Drug: BMS-986278; Placebo and 1 more · For: Healthy Volunteers
Sites: San Antonio, Texas; Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.
Maher TM, Martinez F, Kreuter M, et al. · BMJ Open Respir Res 2026
- LPA1-Induced EMT of Retinal Pigment Epithelial Cells Promotes Subretinal Fibrosis via USP1-Mediated Deubiquitination and Stabilization of ZEB1.
Zhu M, Cui L, Guo Y, et al. · Invest Ophthalmol Vis Sci 2026
- Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant.
Maher TM, Kaminski N, Wang F, et al. · Respir Res 2026
- [Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases].
Witte T, Schupp J · Z Rheumatol 2026
- Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.
Tirelli C, Muscato G, Alaimo C, et al. · J Clin Med 2026
- Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis.
Mansour GK, Hajjar AW, Sukkarieh HH · Front Med (Lausanne) 2026
Also in development for Pulmonary Fibrosis
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.